RecruitingNCT06339255

Italian Observational Study on CAR-T Therapy for Lymphoma

A Multicenter Prospective Observational Study on Chimeric Antigen Receptor (CAR) T-cell Therapy for Lymphoma: Monitoring Feasibility, Efficacy, Toxicity and Biomarkers in a Real Life Setting

Sponsor

Paolo Corradini

Enrollment

5,300 participants

Start Date

Oct 30, 2019

Study Type

OBSERVATIONAL

Conditions

Mantle Cell Lymphoma Follicular Lymphoma Primary Mediastinal Large B-cell Lymphoma (PMBCL)Diffuse Low Grade B-Cell Lymphoma

Summary

The goal of this observational study on chimeric antigen receptor T-cell therapy is to monitor the feasibility, efficacy, toxicity and biomarkers in a real life setting. Partecipants will be asked to agree to their clinical data collection and to partecipate to the optional biological study that aims to evaluate biomarkers of toxicity and response (clinical characteristics, cytokine profile, cellcomposition and type of the CAR-T cell product, lymphoma genomics). The study will evaluate even the disease response according to lugano criteria by PET and CT in routine clinical activity.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This Italian observational study collects real-world data on patients with certain types of lymphoma (blood cancers) who receive CAR-T cell therapy — a cutting-edge treatment where a patient's own immune cells are genetically reprogrammed to attack cancer. No experimental treatment is given; this study observes standard care outcomes. **You may be eligible if...** - You have been diagnosed with diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), mantle cell lymphoma (MCL), or follicular lymphoma (FL) - You are eligible for CAR-T therapy using commercially available products in Italy **You may NOT be eligible if...** - There are no specific exclusion criteria beyond the above eligibility requirements Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.